WO2000001351A1 - Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof - Google Patents
Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof Download PDFInfo
- Publication number
- WO2000001351A1 WO2000001351A1 PCT/US1999/015297 US9915297W WO0001351A1 WO 2000001351 A1 WO2000001351 A1 WO 2000001351A1 US 9915297 W US9915297 W US 9915297W WO 0001351 A1 WO0001351 A1 WO 0001351A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- active agent
- solvent
- skin
- acid
- topical formulation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/324—Boswellia, e.g. frankincense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000557798A JP2002519366A (ja) | 1998-07-07 | 1999-07-07 | 医薬的に活性な作用物質を迅速かつ非刺激的に経皮送達するための組成物、およびそのような組成物の調剤法およびそれらの送達 |
DK99933731T DK1094781T3 (da) | 1998-07-07 | 1999-07-07 | Præparater til hurtig og ikke-irriterende transdermal administration af farmaceutisk aktive midler og fremgangsmåder til formulering af sådanne præparater samt administration deraf |
EP99933731A EP1094781B1 (en) | 1998-07-07 | 1999-07-07 | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
AU49725/99A AU4972599A (en) | 1998-07-07 | 1999-07-07 | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
CA002336682A CA2336682C (en) | 1998-07-07 | 1999-07-07 | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
MXPA00012844A MXPA00012844A (es) | 1998-07-07 | 1999-07-07 | Composiciones para la liberacion transdermica rapida y sin irritacion de agentes farmaceuticamente activos y metodos para formular tales composiciones y liberar los mismos. |
DE69939019T DE69939019D1 (de) | 1998-07-07 | 1999-07-07 | Zusammensetzungen für die schnelle und nicht-irritierende transdermale verabreichung von pharmazeutika and verfahren zur formuliering davon und ihren verabreichung |
US10/831,416 US7267829B2 (en) | 1998-07-07 | 2004-04-23 | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9191098P | 1998-07-07 | 1998-07-07 | |
US60/091,910 | 1998-07-07 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09381095 A-371-Of-International | 1999-07-07 | ||
US09/381,095 A-371-Of-International US6444234B1 (en) | 1998-07-07 | 2000-05-11 | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
US10/074,497 Division US6787152B2 (en) | 1998-07-07 | 2002-02-11 | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000001351A1 true WO2000001351A1 (en) | 2000-01-13 |
Family
ID=22230257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/015297 WO2000001351A1 (en) | 1998-07-07 | 1999-07-07 | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof |
Country Status (12)
Cited By (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001017498A1 (en) * | 1999-09-09 | 2001-03-15 | Pentapharm Ltd. | Use of conjugated linoleic acid (cla) for the topical treatment of cellulite |
WO2001064177A1 (de) * | 2000-02-28 | 2001-09-07 | Henkel Kommanditgesellschaft Auf Aktien | Verwendung von flavonen oder isoflavonen zur cellulite-behandlung |
FR2811566A1 (fr) * | 2000-07-13 | 2002-01-18 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou ses precurseurs ou derives, et une vitamine |
FR2811562A1 (fr) * | 2000-07-13 | 2002-01-18 | Oreal | Composition, notamment cosmetique, renfermant la dhea et un isoflavonoide |
EP1180331A1 (en) * | 2000-08-16 | 2002-02-20 | Unilever N.V. | Blends of isoflavones and flavones |
WO2002034230A1 (fr) * | 2000-10-26 | 2002-05-02 | L'oreal | Composition cosmetique renfermant la dhea et un agent anti-irritant |
WO2002047631A1 (fr) * | 2000-12-15 | 2002-06-20 | L'oreal | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoïde |
NL1017333C2 (nl) * | 2001-02-12 | 2002-08-13 | Gent Natural Products Van | Cosmetisch resp. farmaceutisch preparaat. |
US6607735B2 (en) | 2000-12-21 | 2003-08-19 | Johnson & Johnson Consumer Companies, Inc. | Method for reducing the appearance of dark circles under the eyes |
US6617349B2 (en) | 2000-08-16 | 2003-09-09 | Lipton, Division Of Conopco, Inc. | Blends of isoflavones and flavones |
WO2003082230A2 (en) * | 2002-03-28 | 2003-10-09 | The Procter & Gamble Company | Topical use of vitamin b6 compositions |
FR2855753A1 (fr) * | 2003-06-03 | 2004-12-10 | Dermo Cosmologie Lab De | Composition a base de diosgenine applicable par voie topique |
US6994864B2 (en) | 2000-12-15 | 2006-02-07 | L'oreal | Composition containing 7-hydroxy DHEA and/or 7-keto DHEA and at least a carotenoid |
EP1648406A2 (en) * | 2003-03-11 | 2006-04-26 | Antares Pharma IPL AG | Uses and formulations for transdermal or transmucosal application of active agents |
US7099713B2 (en) | 2002-06-28 | 2006-08-29 | Battelle Memorial Institute | Skin conduction and transport systems |
WO2008036647A1 (en) * | 2006-09-21 | 2008-03-27 | 3M Innovative Properties Company | Antiviral compositions and use thereof |
US7368144B2 (en) | 2000-08-11 | 2008-05-06 | Barry Callebaut France | Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof |
WO2008120207A2 (en) * | 2007-03-29 | 2008-10-09 | Yissum, Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
WO2009120933A2 (en) | 2008-03-28 | 2009-10-01 | Particle Sciences, Inc. | Pharmaceutical solutions and method for solubilizing therapeutic agents |
EP2368562A1 (en) * | 2004-10-08 | 2011-09-28 | Clinuvel Pharmaceuticals Limited | Compositions and methods for inducing melanogenesis in a subject |
EP1800649B2 (fr) † | 2005-12-21 | 2012-10-10 | L'Oréal | Composition cosmétique à effet volumateur |
US8647665B2 (en) | 2006-04-21 | 2014-02-11 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
US8795716B2 (en) | 2001-10-01 | 2014-08-05 | The Procter & Gamble Company | Skin care compositions on a thin sanitary napkin |
US8846649B2 (en) | 2011-11-23 | 2014-09-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US9035123B2 (en) | 2002-10-01 | 2015-05-19 | The Procter & Gamble Company | Absorbent article having a lotioned topsheet |
US9107430B2 (en) | 2008-01-22 | 2015-08-18 | Barry Callebaut Ag | Process for producing red or purple cocoa-derived material |
US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2017027971A1 (en) * | 2015-08-17 | 2017-02-23 | Delivra Inc. | Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions |
US9826770B2 (en) | 2005-03-10 | 2017-11-28 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10220223B2 (en) | 2005-12-21 | 2019-03-05 | L'oreal | Cosmetic composition with a volumizing effect |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471036B2 (en) | 2003-09-09 | 2019-11-12 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10918618B2 (en) | 2005-03-10 | 2021-02-16 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7629384B2 (en) * | 1997-09-17 | 2009-12-08 | Strategic Science & Technologies, Llc | Topical delivery of L-arginine to cause beneficial effects |
US7914814B2 (en) * | 1997-09-17 | 2011-03-29 | Strategic Science & Technologies, Llc | Topical delivery of arginine of cause beneficial effects |
EP1027045A4 (en) * | 1997-10-31 | 2004-12-08 | Arch Dev Corp | METHODS AND COMPOSITIONS FOR REGULATING 5-ALPHA-REDUCTASE ACTIVITY |
US7220427B2 (en) * | 1998-07-08 | 2007-05-22 | Oryxe | Mixture for transdermal delivery of low and high molecular weight compounds |
US6946144B1 (en) * | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
US20060121103A1 (en) * | 2000-05-11 | 2006-06-08 | Kenneth Kirby | Transdermal delivery system |
AU2001282064B2 (en) | 2000-08-03 | 2007-02-01 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
CN1262274C (zh) * | 2000-11-14 | 2006-07-05 | 生命健康科学有限公司 | 磷酸盐衍生物复合物 |
AUPR549901A0 (en) | 2001-06-06 | 2001-07-12 | Vital Health Sciences Pty Ltd | Topical formulation containing tocopheryl phosphates |
US6589591B1 (en) * | 2001-07-10 | 2003-07-08 | Baylor College Of Medicine | Method for treating medical devices using glycerol and an antimicrobial agent |
BR0211673A (pt) * | 2001-07-27 | 2004-07-13 | Vital Health Sciences Pty Ltd | Terapia dermal utilizando derivados de fosfato de agentes de transferência de elétrons |
CA2459647A1 (en) * | 2001-08-20 | 2003-02-27 | University Of Virginia Patent Foundation | Use of s-nitrosothiol signaling to treat disordered control of breathing |
WO2003049774A1 (en) * | 2001-12-13 | 2003-06-19 | Vital Health Sciences Pty Ltd | Transdermal transport of compounds |
US20030199581A1 (en) * | 2002-03-13 | 2003-10-23 | Seligson Allen L. | Boswellin compositions enhanced with 3-beta-acetyl-11-keto-beta-boswellic acid ("AKBA") industrial manufacture and uses |
ES2425392T3 (es) | 2002-03-20 | 2013-10-15 | Mannkind Corporation | Cartucho para un aparato de inhalación |
DE10228680A1 (de) * | 2002-06-27 | 2004-01-22 | Holden Development Limited, Tortola | Grundlage für transdermale Formulierungen (PTF) |
AU2002950713A0 (en) * | 2002-08-09 | 2002-09-12 | Vital Health Sciences Pty Ltd | Carrier |
US20040062794A1 (en) * | 2002-09-30 | 2004-04-01 | Lee Shulman | 17Beta- estradiol/levonorgestrel transdermal patch for hormone replacement therapy |
US20050008664A1 (en) * | 2002-12-06 | 2005-01-13 | Board Of Regents, The University Of Texas System | Compositions and methods related to lipid:emodin formulations |
KR20050086954A (ko) * | 2003-01-17 | 2005-08-30 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | 항증식성 화합물 |
WO2004068107A2 (en) * | 2003-01-21 | 2004-08-12 | Transform Pharmaceuticals, Inc | Apparatus and method for transcellular testing |
US7943166B2 (en) | 2003-04-10 | 2011-05-17 | Neurogesx, Inc. | Methods and compositions for administration of TRPV1 agonists |
US7052715B2 (en) * | 2003-04-11 | 2006-05-30 | All Natural Fmg, Inc. | Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
US7033998B2 (en) * | 2003-04-11 | 2006-04-25 | All Natural Fmg, Inc. | Alcohol-free transdermal insulin composition and processes for manufacture and use thereof |
AU2003901815A0 (en) * | 2003-04-15 | 2003-05-01 | Vital Health Sciences Pty Ltd | Phosphate derivatives |
PT1670433E (pt) | 2003-10-10 | 2012-02-08 | Ferring Bv | Fórmula farmacológica transdérmica para a minimização de resíduos na pele |
US6998109B1 (en) | 2004-01-07 | 2006-02-14 | Pearson Research & Development Limited | Emu-based formulations with lidocaine for wound treatment by inhibiting microbial activity |
WO2005074946A1 (en) * | 2004-02-10 | 2005-08-18 | Adenobio N.V. | Stable and active complexes of adenosine and adenosine phosphates with aminoalcohols for the treatment of pulmonary artery hypertension, cardiac failure and other diseases |
US20050271597A1 (en) * | 2004-02-13 | 2005-12-08 | Keith Alec D | Prostate hypertrophy treatment composition and method |
WO2005081964A2 (en) * | 2004-02-23 | 2005-09-09 | Strategic Science & Technologies, Llc | Topical delivery of a nitric oxide donor to improve body and skin appearance |
WO2005084678A1 (en) * | 2004-03-03 | 2005-09-15 | Vital Health Sciences Pty Ltd | Alkaloid formulations |
CA2561496A1 (en) * | 2004-04-02 | 2005-10-20 | Baylor College Of Medicine | Novel modification of medical prostheses |
US20050226827A1 (en) * | 2004-04-09 | 2005-10-13 | Thienna Ho | Skin lightening composition |
WO2005102307A2 (en) * | 2004-04-19 | 2005-11-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US20110028548A1 (en) * | 2004-04-19 | 2011-02-03 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US9226909B2 (en) | 2004-04-19 | 2016-01-05 | Strategic Science & Technologies, Llc | Beneficial effects of increasing local blood flow |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
US20050272700A1 (en) * | 2004-05-10 | 2005-12-08 | Servet Buyuktimkin | Topical treatment and prevention of human papilloma virus (HPV) infection |
ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
PL1791542T3 (pl) | 2004-08-23 | 2015-11-30 | Mannkind Corp | Sole diketopiperazyny do dostarczania leków |
US9415034B2 (en) * | 2005-01-05 | 2016-08-16 | National Defense Medical Center | Inhibitors and enhancers of uridine diphosphate-glucuronosyltransferase 2B (UGT2B) |
ZA200707492B (en) * | 2005-02-14 | 2009-02-25 | Neurogesx Inc | Device for delivery of TRPV1 agonists |
CA2599424A1 (en) * | 2005-03-03 | 2006-09-08 | Vital Health Sciences Pty Ltd | Compounds having anti-cancer properties |
US20060222690A1 (en) * | 2005-03-30 | 2006-10-05 | Bley Keith R | Low-concentration capsaicin patch and methods for treating neuropathic pain |
US7563464B1 (en) | 2005-04-22 | 2009-07-21 | Bruce Eric Hudkins | Treatment of mucosal membranes utilizing phytoestrogen |
US7252834B2 (en) * | 2005-04-25 | 2007-08-07 | Clemson University Research Foundation (Curf) | Elastin stabilization of connective tissue |
WO2006125642A1 (en) | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
KR20080019228A (ko) * | 2005-06-17 | 2008-03-03 | 바이탈 헬스 사이언시즈 피티와이 리미티드 | 하나 이상의 디 및/또는 모노-(전자전달제) 인산염 유도체또는 그의 착염을 함유하는 담체 |
AU2006290870B2 (en) | 2005-09-14 | 2013-02-28 | Mannkind Corporation | Method of drug formulation based on increasing the affinity of active agents for crystalline microparticle surfaces |
US20070185038A1 (en) * | 2005-09-30 | 2007-08-09 | The Procter & Gamble Company | Regulation of mammalian keratinous tissue using skin care actives |
US7920926B2 (en) * | 2005-12-09 | 2011-04-05 | Apsara Medical Corporation | Method and apparatus for carrying out the controlled heating of tissue in the region of dermis |
TW200800223A (en) * | 2005-12-21 | 2008-01-01 | Shire Pharmaceuticals Inc | Transdermal delivery of meptazinol |
CA2631653A1 (en) * | 2005-12-23 | 2007-06-28 | Vital Health Sciences Pty Ltd. | Compounds having cytokine modulating properties |
BRPI0621248A2 (pt) * | 2006-01-17 | 2011-12-06 | Majid Fotuhi | medicamento e regime de dosagem para prevenção ou redução do risco de permanência ou progressão de demência através de administração de vitaminas especìficas e nsaid |
EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
WO2008044095A1 (en) | 2006-10-11 | 2008-04-17 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate |
JP4869347B2 (ja) * | 2006-07-14 | 2012-02-08 | 国立大学法人北海道大学 | 過冷却促進剤 |
DK2041068T3 (en) | 2006-07-18 | 2017-02-27 | Techfields Biochem Co Ltd | POSITIVELY CHARGED, WATER SOLUBLE PRODRUGS OF IBUPROFEN WITH VERY FAST SKIN PENETRATION SPEED |
PL2046727T3 (pl) | 2006-07-25 | 2014-08-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki diklofenaku o bardzo szybkim stopniu przenikania przez skórę |
PL2049482T3 (pl) | 2006-08-08 | 2016-04-29 | Techfields Biochem Co Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki kwasów arylo- i heteroarylooctowych o bardzo dużej szybkości przenikania przez skórę |
EP2061749B1 (en) | 2006-09-03 | 2018-02-21 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of acetaminophen and related compounds with very fast skin penetration rate |
PL2084132T3 (pl) | 2006-09-03 | 2019-03-29 | Techfields Biochem Co. Ltd | Dodatnio naładowane rozpuszczalne w wodzie proleki z kwasów n-arylantranilowych z bardzo szybką penetracją skóry |
EP2084124B9 (en) * | 2006-10-02 | 2015-07-01 | Techfields Biochem Co. Ltd | Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates |
US20080097557A1 (en) * | 2006-10-19 | 2008-04-24 | Apsara Medical Corporation | Method and apparatus for carrying out the controlled heating of tissue in the region of dermis |
AU2006349528B2 (en) * | 2006-10-23 | 2012-06-07 | Ecolab Inc. | Virucidal composition |
US20100086495A1 (en) * | 2007-02-15 | 2010-04-08 | Derma-Young Ltd. | Compositions and methods for enhancing transmucosal delivery |
AU2007354632B2 (en) | 2007-06-04 | 2014-06-26 | Techfields Inc | Pro-drugs of NSAIAs with very high skin and membranes penetration rates and their new medicinal uses |
JP2010539245A (ja) | 2007-09-14 | 2010-12-16 | 日東電工株式会社 | 薬物担体 |
US20090155337A1 (en) * | 2007-11-12 | 2009-06-18 | Endologix, Inc. | Method and agent for in-situ stabilization of vascular tissue |
JP2011513220A (ja) * | 2008-02-21 | 2011-04-28 | ヴァトリックス・メディカル・インコーポレーテッド | デリバリービヒクルと組み合わせた結合組織安定剤の適用による動脈瘤の処置 |
DK2570147T3 (da) | 2008-06-13 | 2018-01-29 | Mannkind Corp | Tørpulverinhalator og system til lægemiddelindgivelse |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
KR101628410B1 (ko) | 2008-06-20 | 2016-06-08 | 맨카인드 코포레이션 | 흡입 활동에 관한 실시간 프로파일링을 위한 대화형 장치 및 방법 |
KR101372658B1 (ko) | 2008-06-25 | 2014-03-14 | 이엘씨 매니지먼트 엘엘씨 | 피부 및 신체 외관 개선 방법 및 조성물 |
US20100016833A1 (en) * | 2008-07-15 | 2010-01-21 | Ogle Matthew F | Devices for the Treatment of Vascular Aneurysm |
TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
BRPI0913499B1 (pt) | 2008-09-15 | 2020-03-17 | Laila Nutraceuticals | Composições anti-inflamatórias sinergísticas compreendendo extratos de boswellia serrata |
US20100119605A1 (en) * | 2008-11-12 | 2010-05-13 | Isenburg Jason C | Compositions for tissue stabilization |
MX362949B (es) | 2008-12-04 | 2019-02-27 | Yu Chongxi | Composiciones de alta penetracion y sus aplicaciones. |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
US8734845B2 (en) | 2009-06-12 | 2014-05-27 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
US11684624B2 (en) | 2009-06-24 | 2023-06-27 | Strategic Science & Technologies, Llc | Treatment of erectile dysfunction and other indications |
BRPI0925099A2 (pt) | 2009-06-24 | 2018-10-16 | Strategic Science & Tech Llc | composição tópica contendo ibuprofeno |
EP2445493A1 (en) | 2009-06-24 | 2012-05-02 | Strategic Science & Technologies, LLC | Topical composition containing naproxen |
US20110218517A1 (en) * | 2009-10-09 | 2011-09-08 | Ogle Matthew F | In vivo chemical stabilization of vulnerable plaque |
US8444624B2 (en) | 2009-10-19 | 2013-05-21 | Vatrix Medical, Inc. | Vascular medical devices with sealing elements and procedures for the treatment of isolated vessel sections |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
US9554994B2 (en) | 2009-12-16 | 2017-01-31 | Ecolab Usa Inc. | Composition in form of a gel for the virucidal disinfection of mammalian skin |
AU2011213557B2 (en) | 2010-02-05 | 2015-05-07 | Phosphagenics Limited | Carrier comprising non-neutralised tocopheryl phosphate |
EP2536288B1 (en) | 2010-02-15 | 2022-06-22 | Laila Nutraceuticals | A novel boswellia low polar gum resin extract and its synergistic compositions |
US8828377B2 (en) | 2010-03-15 | 2014-09-09 | Laila Nutraceuticals | Boswellia oil, its fractions and compositions for enhancing brain function |
CN102821791B (zh) | 2010-03-30 | 2015-06-17 | 磷肌酸有限公司 | 透皮递送贴剂 |
RU2531455C2 (ru) | 2010-06-21 | 2014-10-20 | Маннкайнд Корпорейшн | Системы и способы доставки сухих порошковых лекарств |
WO2012092523A1 (en) | 2010-12-29 | 2012-07-05 | Strategic Science & Technologies, Llc | Systems and methods for treatment of allergies and other indications |
CN103429247A (zh) | 2010-12-29 | 2013-12-04 | 战略科学与技术有限责任公司 | 勃起功能障碍和其它适应症的治疗 |
US8911468B2 (en) | 2011-01-31 | 2014-12-16 | Vatrix Medical, Inc. | Devices, therapeutic compositions and corresponding percutaneous treatment methods for aortic dissection |
TR201101374A1 (tr) | 2011-02-14 | 2012-09-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Flurbiprofen ve metilsülfonilmetanın topikal farmasötik bileşimleri. |
EP2685992A4 (en) | 2011-03-15 | 2014-09-10 | Phosphagenics Ltd | AMINO-QUINOLINES AS KINASE INHIBITORS |
MY180552A (en) | 2011-04-01 | 2020-12-02 | Mannkind Corp | Blister package for pharmaceutical cartridges |
TR201103183A1 (tr) | 2011-04-01 | 2012-10-22 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Ketoprofen ve metilsülfonilmetanın topikal farmasötik bileşimleri. |
TR201103770A1 (tr) | 2011-04-19 | 2012-11-21 | Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ | Nimesulid ve metilsülfonilmetanin topikalfarmasötik bileşimleri. |
JP2014516695A (ja) | 2011-05-18 | 2014-07-17 | バトリックス・メディカル・インコーポレイテッド | 血管安定化用被覆バルーン |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
WO2013063160A1 (en) | 2011-10-24 | 2013-05-02 | Mannkind Corporation | Methods and compositions for treating pain |
US20140315843A1 (en) | 2011-12-16 | 2014-10-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Topical pharmaceutical compositions of thiocolchicoside and methylsulfonylmethane |
CA3189252A1 (en) | 2012-05-16 | 2013-11-21 | Techfields Pharma Co., Ltd. | High penetration prodrug compositions and pharmaceutical composition thereof for treatment of pulmonary conditions |
US9283241B2 (en) | 2012-07-10 | 2016-03-15 | Clemson University | Treatment to render implants resistant to diabetes |
CA2878457C (en) | 2012-07-12 | 2021-01-19 | Mannkind Corporation | Dry powder drug delivery systems and methods |
WO2014024193A1 (en) * | 2012-08-07 | 2014-02-13 | Prodel Pharma Ltd. | Compositions and methods for rapid transmucosal delivery of pharmaceutical ingredients |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
BR112015023168B1 (pt) | 2013-03-15 | 2021-08-10 | Mannkind Corporation | Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina |
CN114848614A (zh) | 2013-07-18 | 2022-08-05 | 曼金德公司 | 热稳定性干粉药物组合物和方法 |
CA2920488C (en) | 2013-08-05 | 2022-04-26 | Mannkind Corporation | Insufflation apparatus and methods |
CN113350324A (zh) * | 2013-08-21 | 2021-09-07 | 协和大学 | 树状聚合物-白藜芦醇复合物 |
US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US11510859B2 (en) * | 2015-07-16 | 2022-11-29 | Marinomed Biotech Ag | Method for improving aqueous solubility of water-insoluble or slightly water-soluble drugs |
WO2017048807A1 (en) | 2015-09-17 | 2017-03-23 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration or moisturization |
CA3007587C (en) | 2015-12-09 | 2023-12-05 | Phosphagenics Limited | Pharmaceutical formulation |
US10688069B2 (en) | 2016-03-31 | 2020-06-23 | REV Pharmaceuticals LLC | Sports health performance composition |
CN106349206B (zh) * | 2016-08-29 | 2018-09-21 | 珀莱雅化妆品股份有限公司 | 一种从毛喉鞘蕊花中提取福斯高林的制备方法 |
BR112019012946A2 (pt) | 2016-12-21 | 2019-11-26 | Avecho Biotechnology Ltd | processo |
US10385297B2 (en) | 2017-03-16 | 2019-08-20 | The Procter & Gamble Company | Methods for making encapsulate-containing product compositions |
US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053222A (en) * | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
US5523090A (en) * | 1995-02-24 | 1996-06-04 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin treatment composition |
US5529769A (en) * | 1994-12-20 | 1996-06-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions containing betulinic acid |
US5653970A (en) * | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US371683A (en) * | 1887-10-18 | hamlin | ||
US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US3996934A (en) * | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
US4002775A (en) | 1973-07-09 | 1977-01-11 | Kabara Jon J | Fatty acids and derivatives of antimicrobial agents |
US4330551A (en) | 1980-08-26 | 1982-05-18 | Synergetics Co. | Therapeutic method |
US5302611A (en) * | 1980-10-07 | 1994-04-12 | Klaus Keplinger | Oxindole alkaloids having properties stimulating the immunologic system & preparation containing the same |
AU7647581A (en) | 1980-10-07 | 1982-05-11 | K Keplinger | Composition allowing for modifying the growth of living cells, preparation and utilization of such a composition |
US4777074A (en) * | 1985-08-12 | 1988-10-11 | Sumitomo Special Metals Co., Ltd. | Grooved magnetic substrates and method for producing the same |
DE3531545A1 (de) | 1985-09-04 | 1987-03-05 | Goedecke Ag | Arzneimittel mit einem gehalt an calcium-antagonisten und deren verwendung |
US4788062A (en) | 1987-02-26 | 1988-11-29 | Alza Corporation | Transdermal administration of progesterone, estradiol esters, and mixtures thereof |
US4746515A (en) | 1987-02-26 | 1988-05-24 | Alza Corporation | Skin permeation enhancer compositions using glycerol monolaurate |
JP2711549B2 (ja) * | 1987-06-01 | 1998-02-10 | 圭吉 杉山 | 白髪防止・改善用組成物 |
US4789547A (en) | 1987-06-17 | 1988-12-06 | Warner-Lambert Company | Transdermal matrix system |
US4764379A (en) | 1987-08-24 | 1988-08-16 | Alza Corporation | Transdermal drug delivery device with dual permeation enhancers |
US4820720A (en) | 1987-08-24 | 1989-04-11 | Alza Corporation | Transdermal drug composition with dual permeation enhancers |
US4879275A (en) * | 1987-09-30 | 1989-11-07 | Nelson Research & Development Co. | Penetration enhancers for transdermal delivery of systemic agent |
US4855294A (en) | 1988-09-06 | 1989-08-08 | Theratech, Inc. | Method for reducing skin irritation associated with drug/penetration enhancer compositions |
US5332577A (en) | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
US5077284A (en) | 1988-12-30 | 1991-12-31 | Loria Roger M | Use of dehydroepiandrosterone to improve immune response |
DE3902013A1 (de) * | 1989-01-25 | 1990-09-20 | Knoll Ag | Pflaster zur transdermalen anwendung |
US5164416A (en) | 1989-02-03 | 1992-11-17 | Lintec Corporation | Transdermal therapeutic formulation containing a limonene |
AU6034690A (en) * | 1989-07-07 | 1991-02-06 | Atrix Laboratories, Inc. | Benzophenanthridine alkaloids for topical acne treatment |
US5562910A (en) | 1989-09-25 | 1996-10-08 | University Of Utah Research Foundation | Vaccine compositions and method for enhancing an immune response |
US5096715A (en) | 1989-11-20 | 1992-03-17 | Alko Ltd. | Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist |
US5324521A (en) | 1989-12-18 | 1994-06-28 | Dermamed | Systems for transdermal administration of medicaments |
WO1991015241A1 (en) | 1990-03-30 | 1991-10-17 | Yasunori Morimoto | Percutaneously absorbable composition of narcotic and nonnarcotic analgesics |
DE4101515A1 (de) | 1991-01-19 | 1992-07-23 | Henkel Kgaa | Ethersulfate fuer mund- und zahnpflegemittel |
US5230897A (en) | 1991-10-31 | 1993-07-27 | G. D. Searle & Co. | Transdermal pentamidine |
US5460821A (en) | 1993-06-23 | 1995-10-24 | Masiz; John J. | Molecular transdermal transport system |
JP3599766B2 (ja) * | 1993-12-01 | 2004-12-08 | 久光製薬株式会社 | 貼付製剤 |
WO1995031190A1 (fr) * | 1994-05-18 | 1995-11-23 | Hisamitsu Pharmaceutical Co., Inc. | Preparation administrable par voie percutanee pour le traitement des troubles de la miction |
JPH0812519A (ja) * | 1994-06-24 | 1996-01-16 | Kao Corp | 皮膚外用剤組成物 |
JP3533737B2 (ja) * | 1994-12-21 | 2004-05-31 | ライオン株式会社 | 生体老化防止剤及び皮膚用組成物 |
CA2258513A1 (en) * | 1996-07-02 | 1998-01-08 | Beat Schmid | Topical composition comprising a combination of antihistaminic compounds with terpenoid compounds |
CA2264524A1 (en) * | 1996-10-04 | 1998-04-09 | Norihiro Shinkai | Patch |
US6019997A (en) * | 1997-01-09 | 2000-02-01 | Minnesota Mining And Manufacturing | Hydroalcoholic compositions for transdermal penetration of pharmaceutical agents |
-
1999
- 1999-07-07 AT AT99933731T patent/ATE399565T1/de active
- 1999-07-07 EP EP99933731A patent/EP1094781B1/en not_active Expired - Lifetime
- 1999-07-07 AU AU49725/99A patent/AU4972599A/en not_active Abandoned
- 1999-07-07 MX MXPA00012844A patent/MXPA00012844A/es active IP Right Grant
- 1999-07-07 DE DE69939019T patent/DE69939019D1/de not_active Expired - Lifetime
- 1999-07-07 CA CA002336682A patent/CA2336682C/en not_active Expired - Lifetime
- 1999-07-07 PT PT99933731T patent/PT1094781E/pt unknown
- 1999-07-07 JP JP2000557798A patent/JP2002519366A/ja active Pending
- 1999-07-07 ES ES99933731T patent/ES2310042T3/es not_active Expired - Lifetime
- 1999-07-07 WO PCT/US1999/015297 patent/WO2000001351A1/en active Application Filing
- 1999-07-07 DK DK99933731T patent/DK1094781T3/da active
-
2000
- 2000-05-11 US US09/381,095 patent/US6444234B1/en not_active Expired - Lifetime
-
2002
- 2002-02-11 US US10/074,497 patent/US6787152B2/en not_active Expired - Fee Related
-
2004
- 2004-04-23 US US10/831,416 patent/US7267829B2/en not_active Expired - Lifetime
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5053222A (en) * | 1989-06-07 | 1991-10-01 | Shiseido Company Ltd. | Hair cosmetic composition |
US5653970A (en) * | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
US5529769A (en) * | 1994-12-20 | 1996-06-25 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Cosmetic compositions containing betulinic acid |
US5523090A (en) * | 1995-02-24 | 1996-06-04 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Skin treatment composition |
Non-Patent Citations (1)
Title |
---|
DATABASE STN EMBASE 1 January 1900 (1900-01-01), XP002919439, Database accession no. 91290543 * |
Cited By (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100703142B1 (ko) * | 1999-09-09 | 2007-04-05 | 펜타팜아게 | 셀룰라이트의 국소 치료를 위한 공액 리놀레산(cla)의용도 |
WO2001017498A1 (en) * | 1999-09-09 | 2001-03-15 | Pentapharm Ltd. | Use of conjugated linoleic acid (cla) for the topical treatment of cellulite |
US6953583B1 (en) | 1999-09-09 | 2005-10-11 | Pentapharm Ag | Use of conjugated linoleic acid (CLA) for the topical treatment of cellulite |
WO2001064177A1 (de) * | 2000-02-28 | 2001-09-07 | Henkel Kommanditgesellschaft Auf Aktien | Verwendung von flavonen oder isoflavonen zur cellulite-behandlung |
FR2811566A1 (fr) * | 2000-07-13 | 2002-01-18 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou ses precurseurs ou derives, et une vitamine |
FR2811562A1 (fr) * | 2000-07-13 | 2002-01-18 | Oreal | Composition, notamment cosmetique, renfermant la dhea et un isoflavonoide |
WO2002005764A1 (fr) * | 2000-07-13 | 2002-01-24 | L'oreal | Composition, notamment cosmetique, renfermant la dhea et un isoflavonoïde |
WO2002005779A1 (fr) * | 2000-07-13 | 2002-01-24 | L'oreal | Composition, notamment cosmetique, renfermant la dhea et/ou ses precurseurs ou derives, et une vitamine |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7368144B2 (en) | 2000-08-11 | 2008-05-06 | Barry Callebaut France | Method for obtaining cocoa bean polyphenol extracts, resulting extracts and uses thereof |
US6617349B2 (en) | 2000-08-16 | 2003-09-09 | Lipton, Division Of Conopco, Inc. | Blends of isoflavones and flavones |
EP1180331A1 (en) * | 2000-08-16 | 2002-02-20 | Unilever N.V. | Blends of isoflavones and flavones |
US9125816B2 (en) | 2000-08-30 | 2015-09-08 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
US9132089B2 (en) | 2000-08-30 | 2015-09-15 | Besins Healthcare Inc. | Pharmaceutical composition and method for treating hypogonadism |
WO2002034230A1 (fr) * | 2000-10-26 | 2002-05-02 | L'oreal | Composition cosmetique renfermant la dhea et un agent anti-irritant |
FR2815858A1 (fr) * | 2000-10-26 | 2002-05-03 | Oreal | Composition, notamment cosmetique, renfermant la dhea et/ou ses precurseurs ou derives, et un agent susceptible d'inhiber l'irritation d'origine neurogene |
US6852326B2 (en) | 2000-12-15 | 2005-02-08 | L'oreal | Composition, in particular cosmetic, containing 7-hydroxy DHEA and/or 7-keto DHEA and at least an isoflavonoid |
WO2002047631A1 (fr) * | 2000-12-15 | 2002-06-20 | L'oreal | Composition, notamment cosmetique, renfermant la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoïde |
FR2818148A1 (fr) * | 2000-12-15 | 2002-06-21 | Oreal | Composition,notamment cosmetique, renfermant, la 7-hydroxy dhea et/ou la 7-ceto dhea et au moins un isoflavonoide |
US6994864B2 (en) | 2000-12-15 | 2006-02-07 | L'oreal | Composition containing 7-hydroxy DHEA and/or 7-keto DHEA and at least a carotenoid |
US6607735B2 (en) | 2000-12-21 | 2003-08-19 | Johnson & Johnson Consumer Companies, Inc. | Method for reducing the appearance of dark circles under the eyes |
NL1017333C2 (nl) * | 2001-02-12 | 2002-08-13 | Gent Natural Products Van | Cosmetisch resp. farmaceutisch preparaat. |
EP1230911A1 (en) * | 2001-02-12 | 2002-08-14 | Van Gent Natural Products | cosmetic or pharmaceutical preparation |
US8795716B2 (en) | 2001-10-01 | 2014-08-05 | The Procter & Gamble Company | Skin care compositions on a thin sanitary napkin |
WO2003082230A3 (en) * | 2002-03-28 | 2003-11-27 | Procter & Gamble | Topical use of vitamin b6 compositions |
WO2003082230A2 (en) * | 2002-03-28 | 2003-10-09 | The Procter & Gamble Company | Topical use of vitamin b6 compositions |
US7235249B2 (en) | 2002-03-28 | 2007-06-26 | The Procter & Gamble Company | Methods for regulating the condition of mammalian keratinous tissue via topical application of vitamin B6 compositions |
US7099713B2 (en) | 2002-06-28 | 2006-08-29 | Battelle Memorial Institute | Skin conduction and transport systems |
US10687991B2 (en) | 2002-10-01 | 2020-06-23 | The Procter & Gamble Company | Absorbent article having a lotioned topsheet |
US9737446B2 (en) | 2002-10-01 | 2017-08-22 | The Procter & Gamble Company | Absorbent article having a lotioned topsheet |
US9035123B2 (en) | 2002-10-01 | 2015-05-19 | The Procter & Gamble Company | Absorbent article having a lotioned topsheet |
EP1648406A2 (en) * | 2003-03-11 | 2006-04-26 | Antares Pharma IPL AG | Uses and formulations for transdermal or transmucosal application of active agents |
EP1648406A4 (en) * | 2003-03-11 | 2012-03-21 | Antares Pharma Ipl Ag | USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCTIVE APPLICATION OF ACTIVE AGENTS |
WO2004108064A3 (fr) * | 2003-06-03 | 2005-04-07 | Dermo Cosmologie Lab De | Composition a base de diosgenine applicable par voie topique. |
WO2004108064A2 (fr) * | 2003-06-03 | 2004-12-16 | Laboratoire De Dermo-Cosmologie | Composition a base de diosgenine applicable par voie topique. |
FR2855753A1 (fr) * | 2003-06-03 | 2004-12-10 | Dermo Cosmologie Lab De | Composition a base de diosgenine applicable par voie topique |
US10471036B2 (en) | 2003-09-09 | 2019-11-12 | 3M Innovative Properties Company | Antimicrobial compositions and methods |
EP2939686A1 (en) * | 2004-10-08 | 2015-11-04 | Clinuvel Pharmaceuticals Limited | Compositions and methods for inducing melanogenesis in a subject |
EP2368562A1 (en) * | 2004-10-08 | 2011-09-28 | Clinuvel Pharmaceuticals Limited | Compositions and methods for inducing melanogenesis in a subject |
US9826770B2 (en) | 2005-03-10 | 2017-11-28 | 3M Innovative Properties Company | Antimicrobial compositions comprising esters of hydroxycarboxylic acids |
US10918618B2 (en) | 2005-03-10 | 2021-02-16 | 3M Innovative Properties Company | Methods of reducing microbial contamination |
US8911751B2 (en) | 2005-10-11 | 2014-12-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
US10220223B2 (en) | 2005-12-21 | 2019-03-05 | L'oreal | Cosmetic composition with a volumizing effect |
EP1800649B2 (fr) † | 2005-12-21 | 2012-10-10 | L'Oréal | Composition cosmétique à effet volumateur |
US8647665B2 (en) | 2006-04-21 | 2014-02-11 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
WO2008036647A1 (en) * | 2006-09-21 | 2008-03-27 | 3M Innovative Properties Company | Antiviral compositions and use thereof |
WO2008120207A3 (en) * | 2007-03-29 | 2009-01-29 | Yissum Res Dev Co | Compositions for nasal delivery |
WO2008120207A2 (en) * | 2007-03-29 | 2008-10-09 | Yissum, Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
US9107430B2 (en) | 2008-01-22 | 2015-08-18 | Barry Callebaut Ag | Process for producing red or purple cocoa-derived material |
EP2271214A4 (en) * | 2008-03-28 | 2013-01-16 | Particle Sciences Inc | PHARMACEUTICAL SOLUTIONS AND METHOD FOR RESOLVING THERAPEUTICS |
EP2271214A2 (en) * | 2008-03-28 | 2011-01-12 | Particle Sciences, Inc. | Pharmaceutical solutions and method for solubilizing therapeutic agents |
WO2009120933A2 (en) | 2008-03-28 | 2009-10-01 | Particle Sciences, Inc. | Pharmaceutical solutions and method for solubilizing therapeutic agents |
US8987237B2 (en) | 2011-11-23 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10675288B2 (en) | 2011-11-23 | 2020-06-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9248136B2 (en) | 2011-11-23 | 2016-02-02 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US11103516B2 (en) | 2011-11-23 | 2021-08-31 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11793819B2 (en) | 2011-11-23 | 2023-10-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8846648B2 (en) | 2011-11-23 | 2014-09-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8846649B2 (en) | 2011-11-23 | 2014-09-30 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10471148B2 (en) | 2012-06-18 | 2019-11-12 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US10639375B2 (en) | 2012-06-18 | 2020-05-05 | Therapeuticsmd, Inc. | Progesterone formulations |
US10052386B2 (en) | 2012-06-18 | 2018-08-21 | Therapeuticsmd, Inc. | Progesterone formulations |
US11865179B2 (en) | 2012-06-18 | 2024-01-09 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable PK profile |
US8933059B2 (en) | 2012-06-18 | 2015-01-13 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11529360B2 (en) | 2012-06-18 | 2022-12-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11166963B2 (en) | 2012-06-18 | 2021-11-09 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11110099B2 (en) | 2012-06-18 | 2021-09-07 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US8987238B2 (en) | 2012-06-18 | 2015-03-24 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11033626B2 (en) | 2012-06-18 | 2021-06-15 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9006222B2 (en) | 2012-06-18 | 2015-04-14 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9289382B2 (en) | 2012-06-18 | 2016-03-22 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US9012434B2 (en) | 2012-06-18 | 2015-04-21 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US10888516B2 (en) | 2012-12-21 | 2021-01-12 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11241445B2 (en) | 2012-12-21 | 2022-02-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11497709B2 (en) | 2012-12-21 | 2022-11-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11351182B2 (en) | 2012-12-21 | 2022-06-07 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10835487B2 (en) | 2012-12-21 | 2020-11-17 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11304959B2 (en) | 2012-12-21 | 2022-04-19 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11065197B2 (en) | 2012-12-21 | 2021-07-20 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11622933B2 (en) | 2012-12-21 | 2023-04-11 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11123283B2 (en) | 2012-12-21 | 2021-09-21 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US11116717B2 (en) | 2012-12-21 | 2021-09-14 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10206932B2 (en) | 2014-05-22 | 2019-02-19 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US11103513B2 (en) | 2014-05-22 | 2021-08-31 | TherapeuticsMD | Natural combination hormone replacement formulations and therapies |
US10098894B2 (en) | 2014-07-29 | 2018-10-16 | Therapeuticsmd, Inc. | Transdermal cream |
US10258630B2 (en) | 2014-10-22 | 2019-04-16 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10398708B2 (en) | 2014-10-22 | 2019-09-03 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10668082B2 (en) | 2014-10-22 | 2020-06-02 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
US10912783B2 (en) | 2015-07-23 | 2021-02-09 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
WO2017027971A1 (en) * | 2015-08-17 | 2017-02-23 | Delivra Inc. | Transdermal formulations for delivery of berberine compounds, and their use in the treatment of berberine-responsive diseases and conditions |
US9931349B2 (en) | 2016-04-01 | 2018-04-03 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
US10532059B2 (en) | 2016-04-01 | 2020-01-14 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical composition |
WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Also Published As
Publication number | Publication date |
---|---|
AU4972599A (en) | 2000-01-24 |
DE69939019D1 (de) | 2008-08-14 |
DK1094781T3 (da) | 2008-11-03 |
PT1094781E (pt) | 2008-10-08 |
JP2002519366A (ja) | 2002-07-02 |
ATE399565T1 (de) | 2008-07-15 |
CA2336682C (en) | 2006-10-10 |
US7267829B2 (en) | 2007-09-11 |
EP1094781A1 (en) | 2001-05-02 |
US20030104040A1 (en) | 2003-06-05 |
EP1094781B1 (en) | 2008-07-02 |
CA2336682A1 (en) | 2000-01-13 |
US20040202709A1 (en) | 2004-10-14 |
US6444234B1 (en) | 2002-09-03 |
US6787152B2 (en) | 2004-09-07 |
MXPA00012844A (es) | 2004-05-21 |
EP1094781A4 (en) | 2007-01-17 |
ES2310042T3 (es) | 2008-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6444234B1 (en) | Compositions for rapid and non-irritating transdermal delivery of pharmaceutically active agents and methods for formulating such compositions and delivery thereof | |
US10646526B2 (en) | Cannabis extraction method and compositions | |
Pawar et al. | Phytosome as a novel biomedicine: a microencapsulated drug delivery system | |
JP4652806B2 (ja) | 局所用薬剤キャリアー | |
Burki et al. | Formulation development, characterization, and evaluation of a novel dexibuprofen-capsaicin skin emulgel with improved in vivo anti-inflammatory and analgesic effects | |
Surber et al. | The mystical effects of dermatological vehicles | |
EP0954278A1 (en) | Pharmaceutical compositions containing kukui nut oil | |
CN107158086B (zh) | 具有缓解瘙痒功效的皮肤养护/治疗组合物 | |
US20060121103A1 (en) | Transdermal delivery system | |
PT1392335E (pt) | Composições farmacêuticas e/ou cosméticas para o tratamento de celulite e adiposidades localizadas | |
CN106619588A (zh) | 一种含辅酶q10的自微乳型营养组合物、制备方法及用途 | |
CN110974861B (zh) | 一种艾纳香油脂质体 | |
US11344598B2 (en) | Herbal nanoformulations for treating psoriasis and other skin conditions | |
CN105848666A (zh) | 疼痛缓解制剂以及治疗方法 | |
Gaikwad et al. | Formulation design and evaluation of an emulgel containing Terminalia arjuna bark extract for transdermal delivery | |
Tripathi et al. | Pharmacokinetic-interaction of Vitex negundo Linn. & paracetamol | |
CN108743534B (zh) | 一种雷公藤红素或雷公藤红素衍生物囊泡及其制备方法 | |
CN105287742A (zh) | 一种防治蚊虫叮咬的药膏及其制备方法 | |
EP0048280A1 (en) | Skin and nail composition containing phosphate-trialkanolamine complex | |
CN108685926A (zh) | 包含化学消融剂和生物活性苷的药物组合物及其用途 | |
Ruiz et al. | Skin creams made with olive oil | |
Sapra et al. | Role of volatile oil pretreatment and skin cholesterol on permeation of ion-paired diclofenac sodium | |
Saroha et al. | A Future Trend Towards the Enhancement of Bioavailability: Phytosomes | |
Khokhlenkova et al. | Development of ointment composition with dense oak bark extract | |
JP4555423B2 (ja) | 抗炎症性クリーム |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 09381095 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/012844 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 557798 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref document number: 2336682 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999933731 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999933731 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |